157 results about "Pancreatic lipase" patented technology

The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from Candida cylindracea, alone or in combination with amylase or amyloglucosidase, protease and / or lactase. Furthermore, the invention discloses methods for treating pancreatic enzyme insufficiency comprising administering compositions to patients in need thereof.

The invention relates to compositions comprising three inhibitors, one pancreatic lipase inhibitor, an alpha glucosidase inhibitor, and a sodium dependent glucose transporter inhibitor. The invention also provides methods of using the compositions for controlling glucose and lipid uptake.

The invention describes the preparation, isolation and use of an extract of kiwi fruit for the treatment of a disease or condition related with, caused by or mediated by activity of human pancreatic lipase and / or human fatty acid synthase.

The invention discloses a feed additive for improving the digestion utilization ratio of fat and a method for preparing the same. The feed additive comprises the following components in weight portion: 0 to 35 portions of bile acid, 0 to 15 portions of taurine and 20 to 80 portions of defatted rice bran. The invention has the advantages that: by practice, we finds that if proper amount of bile acid and taurine is added in the feed, the activity of pancreatic lipase is enhanced, the digestion utilization ratio of fat is greatly improved, the liver function is strengthened, the incidence rate of animal fatty liver and the death rate of animals are lowered, so that the addition level of fat in the feed can be reduced, and the aim of saving feed cost is achieved. In poultry breeding, the utilization ratio of fat is improved by 10 to 25 percent; in pig feeding, the utilization ratio of fat is improved by 10 to 25 percent; and in the fish, the utilization ratio of fat is improved by 10 to 25 percent, and the incidence rate of liver-gall syndrome of fish is greatly lowered.

The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from Candida cylindracea, alone or in combination with amylase or amyloglucosidase, protease and / or lactase. Furthermore, the invention discloses methods for treating pancreatic enzyme insufficiency comprising administering compositions to patients in need thereof.

Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.

The invention discloses a novel production process of pancreatin, belonging to the technique of medicine manufacturing. The production process comprises the following steps of: unfreezing raw materials, polishing tablets, grinding into pulp, activating, separating, filtering, precipitating, squeezing, degreasing, palletizing, drying and crushing, wherein 0.2-0.5% CaCl2 is adopted as an activating agent in the step of activation, a 10-30% acetone solution is adopted for extraction, the extraction temperature is 5-15 DEG C, and the time is 8-20 hours. The productivity of pancreatin produced by using the production process is remarkably improved, and the ratios of pancreatic lipase and amylopsin are remarkably improved; and on such basis, the steps are further adjusted and optimized, so that the steps cooperate with one another so as to obtain a complete optimized production process, the pancreatin yield is about 14%, and the main indexes are that the trypsin content is about 3600 U / g, the amylopsin is about 100000 U / g, and the pancreatic lipase content is about 43000 U / g, and achieve the standard of exported pancreatin.

The invention provides an application of a mangiferin compound with a structure shown as a formula I as a pancreatic lipase inhibitor, an application of a mango extract containing the mangiferin compound with the structure shown as the formula I as a pancreatic lipase inhibitor, and an application of the mangiferin compound with the structure shown as the formula I or the mango extract containing the mangiferin compound with the structure shown as the formula I to preparation of a medicament or a food for treating and / or preventing obesity, and provides an application of the mangiferin compound with the structure shown as the formula I or the mango extract containing the mangiferin compound with the structure shown as the formula I to preparation of a medicament or a food for treating and / or preventing obesity. The mangiferin compound has the function of inhibiting the activity of pancreatic lipase, so that the occurrence of obesity can be avoided by inhibiting the accumulation of in-vivo fat. Meanwhile, the mangiferin compound has wide physiological activity, so that side effects on human bodies caused by the conventional weight-losing product can be avoided.

Disclosed are a microcapsule fat powder of Ω3-enriched meat, egg and milk and its preparation method, and the powder includes a water-soluble wall material and an Ω3 oil core material embedded in the wall material. The water-soluble wall material is prepared by mixing dextrin, water-soluble syrup, whey powder or chitosan with starch paste, and the Ω3 oil core material is prepared by mixing linseed oil, deep sea fish oil or algae oil with a composite emulsifier which is stearic acyl lactylate. The microcapsule fat powder can be combined with intestinal and pancreatic lipases very easily to improve the digestion, absorption and utilization of Ω3 oils.

The invention relates to a method for catalytic synthesis of arbutin by using dissociative or immobilized Porcine pancreatic lipase. The method comprises the process steps of selection of a reaction system, preparation of immobilized lipase, optimization of reaction conditions, extraction of a product, etc. According to the invention, hydroquinone and sugar mixed according to a mol ratio of 1: 1 to 1: 5 are added into a reaction medium, and lipase is used as a catalyst for a reaction; the reaction lasts for 10 to 120 h at a temperature of 20 to 60 DEG C, and a conversion rate of arbutin is as high as more than 95%; and the usage amount of lipase is 0.01 to 5 times of the weight of sugar. Arbutin is synthesized under the catalysis of dissociative or immobilized lipase in the method for the first time, and the method has the advantages of mild reaction conditions, repeated usability of lipase, a short production period, a simple extraction process for the product, etc., thereby enabling production cost to be substantially reduced.

A novel form of lipase, namely feline pancreatic lipase (also termed feline classical pancreatic lipase) has an N-terminal amino acid sequence as shown in SEQ ID NO. 1. A method of purifying this lipase includes collecting pancreatic tissue from cats, delipidating the pancreatic tissue to produce a delipidated pancreatic extract, extracting pancreatic lipase from the delipidated pancreatic extract, and eluting the extracted pancreatic lipase through various columns. This lipase can be used for measuring pancreatic lipase immunoreactivity in serum thereby diagnosing pancreatitis in cats. To do so, antiserum against feline pancreatic lipase is prepared, and immunoassays are then performed in serum samples using this antiserum. In the event that increased concentration of pancreatic lipase immunoreactivity above the control range is detected in the serum, the cat might have pancreatitis.

The invention provides application of an aqueous fructus amomi extract and olatile oil in preparation of a drug for losing weight and reducing blood fat. Fructus amomi is smashed, soaked and decocted to obtain an aqueous extract, or the fructus amomi (Amomun villosum Lour) is smashed and soaked, and the volatile oil is extracted and collected through a steam distillation method. The obtained anti-obesity drug adopts raw materials with homology of medicine and food, has the effects of controlling the obesity induced by high fat diet, relieving hyperlipidaemia in an obesity state, inhibiting the high serum endotoxin state in the obesity state and inhibiting pancreatic lipase and can well achieve the purpose of healthily reducing the fat.

The invention discloses an immobilized porcine pancreatic lipase carrier, which is a macroporous bead crosslinked polymer containing succinimidyl ester groups and has a structure represented by the formula I. The carrier forms a high polymer with acrylic acid as a reactive monomer and N,N'-methylenebisacrylamide as a crosslinking agent, and in the meantime, incorporates the succinimidyl ester active group so that the time required for immobilizing the porcine pancreatic lipase is short, namely only 1 hour is required, and the immobilizing efficient is high and stability of activity retention of the immobilized enzyme is excellent; the apparent activity of the immobilized enzyme is high and can reach 750U / g and above. The invention also discloses a preparation method and application of the immobilized porcine pancreatic lipase carrier.

A method of producing a phytomedicinal therapeutic for the prevention and control of a disease selected from the group consisting of obesity, cardiovascular disease, and diabetes, and conditions related thereto is provided which comprises extracting peanut shells with a solvent, removing a substantial portion of the solvent to produce a concentrated extract. Phytomedicinal compositions are provided that comprise an effective amount of at least one coumarin compound or one coumarin derivative derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL). Phytomedicinal compositions are provided that comprise at least an effective amount of coumarin derivatives (6,7-dihydroxycoumarin-esculetin, and esculetin-like compounds). A method for the prevention and / or treatment of treatment of a condition selected from the group consisting of obesity, cardiovascular disease, and diabetes, is provided which comprises administering a composition comprising an effective amount of at least one coumarin derivative, including 6,7-dihydroxycoumarin (esculetin), derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL).

The invention belongs to the technical field of medicaments, and in particular relates to application of isopentene group flavonoid compound used as a pancreatic lipase inhibitor. The flavonoid compound has the following structural formula and has a chemical name of: (E)-2-(2,4-dihydroxy phenyl)-5,7-dihydroxy-3-(3-methyl-2-butenyl)-6-(3-methy-l-butenyl)-4H-chromene-4-ketone, and can be extracted from artocarpus nitidus. Pancreatic lipase activity tests and experiments of weight loss action in animals prove that the compound has obvious pancreatic lipase inhibitory activity and weight loss action, can be taken as the lead compound for developing novel medicaments for preventing or curing obesity and related metabolic diseases, and also can be used for preparing the medicaments for preventing and curing clinically common multiple obesity and the related metabolic disease.

A method and device for determining pancreatic lipase in an animal blood sample. In one aspect, the device includes a compartmentalized container for storing and reacting the reagents for use in the assay. In another aspect, the device include a multilayer device having a spreading layer and reagents layers with dried reagents for detecting pancreatic lipase. The devices also includes a system for the optical determination of a color change in the reaction mixture. The method includes the use of the device to detect pancreatic lipase in samples.

The present invention relates to enyne bromide compounds (with structural formula shown below) and preparation method and use thereof. Vitro biological activity test shows such compounds significantly inhibit the activity of pancreatic lipase, and can be used as a new drug lead compound for prevention or therapeutic treatment of obesity and related metabolic disorders and used for the preparation of the drug for clinical treatment of common obesity and related metabolic diseases.

The invention provides a peptide with a pancreatic lipase inhibitor effect. The sequence of the peptide is selected from SEQ ID NO.1-5; the invention also provides application of the peptide in preparation of medicines, foods and health-care products for treating hyperlipemia. The peptide is a plant-derived, non-toxic and harmless natural substance, and experiments prove that the peptide has remarkable pancreatic lipase inhibitory activity and lipid-lowering effect; the compound is clear in action mechanism and definite in target spot, is expected to become a substitute medicine for preventing and treating hyperlipemia, and has a good market prospect in the industries of medicine and functional food.

The invention discloses a nymphaea hybrid extract and application of a nymphaea hybrid extract composition. The application includes preparation of food, healthy food and medicines for inhibiting pancreatic lipase activity and improving intestinal flora and preparation of food, healthy food and medicines for preventing obesity or reducing weight, wherein preventing obesity or reducing weight and lipid includes inhibiting pancreatic lipase activity, improving weight, regulating blood lipid and improving intestinal flora, and improving intestinal flora includes improving intestinal microorganism abundance and diversity and improving intestinal flora structures. The nymphaea hybrid extract composition is formed by combination of at least one of nymphaea hybrid extract, lotus leaf extract, green tea extract, semen cassiae extract and grape seed extract, wherein the weight content of the nymphaea hybrid extract in the compositiosn is larger than or equal to 20%.

The invention provides a hair conditioner easy to clean, and belongs to the technical field of daily chemical products. The hair conditioner easy to clean is prepared from mustard, sesame oil, emulsion, vegetable protein, enzymolysis chitosan liquid, a compound enzyme, dimethyl siloxane, preservative, water and essence, wherein the emulsion is formed by mixing (N-amidino)dodecyl-acrylamide and polyethylene glycol derivative, and adding paradichlorobenzene and ferrocene for a stirring reaction, the enzymolysis chitosan liquid is obtained by mixing and swelling chitosan and water, and adding chitosanase for constant-temperature stirring and anzymolysis and enzyme deactivation, the compound enzyme is formed by compounding pancreatic lipase and ceratinase, and the hair conditioner easy to clean is obtained after adding the mustard, the sesame oil, the emulsion, vegetation protein, the enzymolysis chitosan liquid, compound enzyme, dimethyl siloxane, the preservative, the water and the essence into a blender mixer to be mixed. After being utilized, the hair conditioner is easy to clean and has an excellent hair care effect.

The invention discloses a selective method for selecting the pancrelipase inhibitor from Chinese traditional medicine. The method is to enclose the pancrelipase on the Millipore enzyme standard board; by adding the activator, the pancrelipase can be transferred into the active open structure; after washing, the Chinese traditional medicine extraction is added to culture to remove the uncombined or weakly combined things; after washing, the substrate is added to react and detect the fluorescence intensity of product and compute the inhibiting percent of sample. The method can be used to select the Chinese traditional medicine extraction and decrease the false masculine result made by the surfactant and nonspecific thing in sample to improve the selective hit rate.

The invention discloses a mesoporous biomaterial containing porcine pancreatic lipase and a preparation method of the mesoporous biomaterial. The method comprises the steps of dissolving surfactant in water solution of hydrochloric acid, adding inorganic silicon source and organic silylating reagent, fully hydrolyzing under a water bath condition, aging, cooling, filtering, washing, drying and extracting the surfactant to obtain mesoporous silica containing an active group, then putting the prepared material into buffer solution of porcine pancreatic lipase, centrifuging, filtering and drying to obtain the mesoporous biomaterial with functionalized porcine pancreatic lipase. The method disclosed by the invention is simple and environment-friendly. The synthetic mesoporous biomaterial containing the porcine pancreatic lipase has the characteristics of large aperture, high specific surface area, high enzyme activity and large enzyme activity increasing proportion, and can be directly used as biological catalytic material. The mesoporous biomaterial containing the porcine pancreatic lipase disclosed by the invention has wide application prospect in these respects of not only bioreactors, but also nano-bio-sensors, biomolecular delivery and the like.

The invention discloses a porcine pancreatic lipase-inorganic hybrid nanoflower catalyst, a preparing method thereof, and applications of the catalyst in biodiesel preparation, and belongs to the technical field of biological energy. The method includes adding 1-5 mL of an aqueous CuSO4 solution having a concentration of 80-300 mM into 100 mL of a PBS buffer solution the pH of which is 6-8 and into which 10-250 mg of porcine pancreatic lipase is dissolved; performing incubation at 0-30 DEG C for 24-72 h; then performing centrifugal separation; washing an centrifugation product with deionized water for 3-5 times; freeze-drying the product to obtain the catalyst; and storing the catalyst at -20 DGE C. The weight percentage of the porcine pancreatic lipase in the catalyst is 12-31%. Accordingto the method, no organic agent is used in a nanometer catalyst preparing stage, thus maintaining enzyme activity well and improving enzyme tolerance. In addition, the novel catalyst can avoid a complex separation process in biodiesel synthesis, and has a good reutilization efficiency.

The invention relates to a laurane type sesquiterpene compound or a derivative thereof extracted and separated from a sea plant Laurencia okamurai in the East China Sea, and a preparation method and application thereof. The structural formula of the laurane type sesquiterpene compound or the derivative thereof is shown as above: when R1, R2 and R3 are hydrogen at the same time, the sesquiterpene compound or the derivative thereof is laurinferol, and when R4 is hydrogen, the sesquiterpene compound or the derivative thereof is aplysin. In vitro tests show that the sesquiterpene compound or the derivative thereof has obvious pancreatic lipase inhibition activity and is expected to be applied to preparing medicaments for preventing or treating decompensation diseases including adiposis, diabetes, hyperlipoidemia, fatty liver and the like. The sesquiterpene compound or the derivative thereof can also provide a lead compound for developing the new medicaments for preventing and treating the decompensation diseases, and is significant for developing and utilizing marine biological resources of China.

The invention discloses an application of porcine pancreatic lipase as a catalyst of asymmetric aldol reaction of heterocyclic ketone and aromatic aldehyde. The aromatic nucleus of the aromatic aldehyde is connected with an electron withdrawing substituent, and the aromatic aldehyde has the advantages of good catalytic activity, high enantiomeric selectivity, environmental friendliness, good economical performance and the like. The invention also provides a method of using the porcine pancreatic lipase to catalyze the asymmetric aldol reaction of the heterocyclic ketone and the aromatic aldehyde, the yield is high, and the ee (enantiomeric excess) value is high. The scope of application of the porcine pancreatic lipase is broadened, a potentially excellent catalyst is provided for the asymmetric aldol reaction, and the porcine pancreatic lipase has broad application prospects in the field of asymmetric synthesis.

A Chinese and western composite medicine for treating neoplastic diseases is characterized by comprising Chinese herbal medicinal ingredients and a western medicinal ingredient which are mixed, the Chinese herbal medicinal ingredients include 5 polyzyme tablets and a stomach invigorating and digestion aiding tablet, each polyzyme tablet comprises pepsin, trypsin, pancreatic lipase and amylopsin, and the stomach invigorating and digestion aiding tablet comprises radix pseudostellariae, tangerine peels, Chinese yam, (roasted) malt and hawthorn; the western medicinal ingredient is ceftriaxone sodium injection solution; and the weight of each polyzyme tablet is 0.313g, the total weight of the polyzyme tablets is 1.57g, the weight of the stomach invigorating and digestion aiding tablet is 0.8g, the weight of the ceftriaxone sodium injection solution is 0.75g, and the Chinese herbal medicinal ingredients and the western medicinal ingredient are combined to form the prescription. The Chinese and western composite medicine for treating the neoplastic diseases is particularly used for suppressing and killing pathogenic bacteria capable of causing benign tumor and malignant tumor infection of tissue cells of a human body, the composite medicine is directly dripped into the oral cavity or an affected part of the human body when the human body suffers from the tumor infection, and 3-4 drops of the composite medicine are applied every time. The Chinese and western composite medicine has few side effects, becomes effective within 30 minutes and does not injure the liver, the brain and the kidneys of the human body.

The invention describes the preparation, isolation and use of an extract of kiwi fruit for the treatment of a disease or condition related with, caused by or mediated by activity of human pancreatic lipase and / or human fatty acid synthase.

The invention discloses a production method of a fat-reducing peptide, and relates to functional health food and a preparation method thereof. The fat-reducing peptide belongs to the health food which is abundant in biological active peptides, healthy, safe, abundant in nutrition, stable and easy to store, convenient to eat and suitable of industrial production and has good fat-reducing function. The preparation method of the fat-reducing peptide comprises: (1) pretreatment on fish flesh; (2) extraction of fish flesh water-soluble protein; and (3) preparation of the fat-reducing peptide. The prepared fat-reducing peptide has obvious effect of inhibiting the activity of pancreatic lipase and amylase, and animal in-vivo experiments confirm that the fat-reducing peptide has obvious blood fat reducing effect and is capable of improving the antioxidation level of liver, improving liver damage and reducing body weight increase, and the fat-reducing peptide is ideal functional health food possessing the characteristics of reducing blood fat, reducing weight, and being nutritive, healthy and suitable to people of all ages.

The invention discloses a method for preparing immobilized lipase by using porous nano-gold as a carrier, and application of the immobilized lipase. According to the method, the porous nano-gold material is prepared by using a dealloying method; the method comprises the steps of firstly, modifying by using alpha-lipoic acid so as to form a carboxylated nano-gold material; modifying the carboxylated nano-gold material by using a coupling agent so as to form a nano-gold compound terminated by N-hydroxysulfosuccinimide sodium salt; immobilizing porcine pancreatic lipase onto the nano-gold compound. The immobilized lipase prepared by the method has good catalytic activity, pH stability and thermal stability; compared with resolvase, the immobilized lipase has obviously improved storage stability; furthermore, after being subjected to simple treatment, the carrier can be recycled, so that the cost is lowered.

It is an object of the present invention to provide: a dry analytical element for analyzing pancreatic lipase wherein the triglyceride is not transcribed on the support to contaminate a transportation slip or other analytical elements and wherein an additive solution of the triglyceride neither reaggregates nor precipitate, so that the dry analytical element is stable and is compatible with production. The present invention provides a dry analytical element for measuring pancreatic lipase contained in body fluid, which comprises triglyceride of long chain alkyl fatty acid having 12 to 22 carbon atoms, monoglyceride lipase, and a glycerin measurement reagent, and which comprises a water-impermeable support and at least one spreading or reagent layer, wherein a hydrophilic polymer at a weight ratio of 1.8:1 or greater with respect to the triglyceride is contained.